The emerging science of the microbiome is still in its infancy, yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps our survival.
In this webinar, Larry Weiss will present early metagenomic and metatranscriptomic results from research on the skin and gut microbiomes of an isolated tribe of Yanomami hunter-gatherers living deep in the Venezuelan Amazon who have a low incidence of skin cancer, inflammatory disease, and diabetes. Weiss and colleagues collected and analyzed over 500 skin, gut, and oral samples, finding a large proportion of novel organisms. With metatranscriptomic analyses, the team found that the Yanomami microbiomes express metabolic pathways lost to industrialized populations. Weiss’s presentation will focus on skin microbiomes, and he will discuss the shift from using metagenomics to metatranscriptomics to understand the pathways driving health.
CEO and Founder
Weiss Bioscience, Inc.
Larry Weiss is the CEO and founder of Weiss Bioscience, a San Francisco-based microbiome research and development company and the manufacturer of Symbiome Skincare products.He was the founding chief medical officer at AOBiome where he formulated AOB-101, the first live topical therapeutic, and Mother Dirt AO Mist, the first probiotic cosmetic. While at AOBiome, he ran the first successful remote clinical trial in collaboration with Science 37. Before that, he was the founder and CSO of CleanWell Company. He has an extensive background in natural products chemistry, microbiology, clinical medicine, biophysics, pharmaceutical, and skin care product development. He has a medical degree from Stanford University and a bachelor’s degree in biochemistry from Cornell University. He has over 26 patents and is published in the areas of chemistry, electrophysiology, clinical pharmacology, and the microbiome. He is also the founding chair of The Global Microbiome Council.
Chief Executive Officer
Manoj Dadlani serves as chief executive officer at CosmosID, a Maryland-based provider of solutions for unlocking the microbiome. Previously, Dadlani served as a partner at Applied Value Group, a management consulting and investment firm, and was co-founder and CEO at Rasa Industries, a beverage manufacturing company. Dadlani has experience in strategy, M&A, supply chain management, product development, marketing, and business development. Dadlani received his bachelor’s and master’s degrees in biological engineering from Cornell University. Services offered by CosmosID’s CLIA certified and GLP laboratory cover the entire workflow from study design to sample collection, extraction, library preparation, sequencing, data analysis, and publication support. CosmosID’s cloud-based metagenomics application offers user-friendly access to the largest curated databases for microbial genomics, antimicrobial resistance, and virulence data and has been independently validated to return metagenomic analyses at strain level resolution with sensitivity and precision.